Author:
Teleginski Lilian Klein,Maciel Aline Biggi,Mendes Cassiana,Silva Marcos Antônio Segatto,Bernardi Larissa Sakis,de Oliveira Paulo Renato
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution in the in vivo bioavailability. Pharm Res. 1995;12:413–20.
2. Bergström CAS, Andersson SBE, Fagerberg JH, Ragnarsson G, Lindahl A. Is the full potential of the biopharmaceutics classification system reached? Eur J Pharm Sci. 2014;57:224–31.
3. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3:631–43.
4. Cook JA, Davit BM, Polli JE. Impact of biopharmaceutics classification system-based biowaivers. Mol Pharm. 2010;7:1539–44.
5. BRAZIL, Agência Nacional de Vigilância Sanitária (ANVISA). Resolução - RDC Nº 37, de 3 de agosto de 2011. Dispõe sobre o Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências, Brasília, Brazil, 2011. http://www.brasilsus.com.br/legislacoes/anvisa/109151-37.html . Accessed 10 Mar 2014.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献